Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has returned with a vengeance. You knew this would happen, yes? To cope, as always, we are quaffing multiple cups of stimulation. Our choice today is Jack Daniels — yes, such a thing exists. Look it up, if you must. Meanwhile, here are some tidbits. Hope your day is simply smashing and do keep us in mind when you run across anything fascinating …

Novartis (NVS) promised to take “fast and decisive action” should an investigation into alleged bribery in Greece find that its managers engaged in unethical or illegal conduct, Reuters writes. The drug maker is in the midst of a bribery probe in which Greek prosecutors in early 2017 raided its offices in Athens. Meanwhile, Switzerland’s Federal Office of Justice confirmed receiving two requests for legal assistance from Greece and the United States concerning probes into Novartis and alleged bribes the drug maker paid to Greek doctors and public officials, Ekathimerini says.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.